Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

KALV
KalVista Pharmaceuticals, Inc. Common Stock
stock NASDAQ

Inactive
Jun 10, 2026
27.00USD+0.037%(+0.01)4,272,770
Pre-market
0.00USD-100.000%(-26.99)0
After-hours
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
09:23AM EST  KalVista Pharmaceuticals Granted U.S. Patent #11,230,537 'Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxo- pyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors'   Benzinga
Jan 24, 2022
07:32AM EST  KalVista Pharmaceuticals Highlights Publication Of Oral HAE Therapy KVD900 Phase 1 Data In Journal Of Allergy And Clinical Immunology   Benzinga
Jan 4, 2022
07:06AM EST  KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
Dec 10, 2021
05:41AM EST  Needham Maintains Buy on KalVista Pharmaceuticals, Lowers Price Target to $48   Benzinga
Dec 9, 2021
09:55PM EST  KalVista Pharmaceuticals: Q2 Earnings Insights   Benzinga
09:45PM EST  KalVista Pharmaceuticals Q2 EPS $(0.80) vs $(0.58) YoY; Revenue $0   Benzinga
Dec 3, 2021
07:00AM EST  KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Nov 10, 2021
08:23AM EST  The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance   Benzinga
06:38AM EST  KalVista Pharmaceuticals Provides Progress Update On KVD900; End-Of-Phase 2 Meeting Completed, Phase 3 Trial Dosing Expected Q1 2022   Benzinga
06:38AM EST  KalVista Updates On KVD900 For Oral On-Demand Treatment Of Hereditary Angioedema; Finalizes Phase 3 Trial Protocol   RTTNews
06:30AM EST  KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema   Business Wire
Nov 9, 2021
07:00AM EST  KalVista Pharmaceuticals to Present at Upcoming Investor Conferences   Business Wire
Nov 8, 2021
06:38AM EST  KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure And Improves Outcomes As Oral On-Demand Treatment Of HAE   Benzinga
Nov 4, 2021
07:00AM EDT  KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Sep 21, 2021
07:00AM EDT  KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference   Business Wire
Sep 14, 2021
07:07AM EDT  KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's Phase 2 clinical trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE).   RTTNews
06:53AM EDT  KalVista: FDA Lifts Clinical Hold On Phase 2 Clinical Trial Of KVD824 For Hereditary Angioedema   RTTNews
06:30AM EDT  KalVista Pharmaceuticals Announces the Lifting Of FDA Clinical Hold For Phase 2 Trial Of KVD824   Benzinga
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
06:34AM EDT  KalVista Pharmaceuticals Q1 EPS $(0.66) Down From $(0.61) YoY   Benzinga
Sep 2, 2021
04:09PM EDT  KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Aug 23, 2021
06:33AM EDT  KalVista Pharma Says Co Submitted its Clinical Hold Response to the FDA Related to the US IND Filings for KVD824   Benzinga
06:32AM EDT  KalVista Pharma Says its Phase 2 Trial of KVD824 Received Regulatory Approval in Canada, Australia and the UK, Expects Patient Enrollment in Q3 2021   Benzinga
Aug 9, 2021
07:17AM EDT  KalVista Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
07:00AM EDT  KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Jul 15, 2021
10:27AM EDT  UPDATE: Roth Capital On KalVista Buy Reiteration: Firm Remains Bullish On Co.'s On-Demand HAE Treatment Following Phase 2 Data With Significant Results Shown In Comparison To Placebo As Symptom Relief Occurred At 1.6 Hours Vs. 9 Hours Respectively   Benzinga
10:26AM EDT  Roth Capital Reiterates Buy Rating On KalVista Pharmaceuticals With $55 Price Target   Benzinga
Jul 13, 2021
06:32AM EDT  KalVista Pharmaceuticals Q4 EPS $(0.65) Down From $(0.37) YoY   Benzinga
Jul 12, 2021
07:43AM EDT  KalVista Pharma Presents Phase 2 Data For KVD900 At EAACI Congress   RTTNews
07:37AM EDT  KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE   Benzinga
Jun 28, 2021
07:00AM EDT  KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)   Business Wire
Jun 7, 2021
10:10AM EDT  KalVista Pharma Saturday Highlights Oral Presentation OF Clinical Data Support KVD900 As Oral On-Demand Treatment For Hereditary Angioedema   Benzinga
Jun 5, 2021
01:11PM EDT  KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop   Business Wire
May 27, 2021
07:00AM EDT  KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference   Business Wire
May 10, 2021
07:21AM EDT  KalVista Pharmaceuticals To Present Clinical Data Of KVD900 For The Oral Treatment Of Hereditary Angioedema At The 12th C1-Inhibitor Deficiency & Angioedema Workshop   Benzinga
May 3, 2021
07:16AM EDT  KalVista Pharma Appoints Paul Audhya As Chief Medical Officer   RTTNews
07:00AM EDT  KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer   Business Wire
Apr 23, 2021
03:06PM EDT  KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
06:44AM EDT  KalVista Pharmaceuticals Announces FDA Has Notified Co. It Has Placed Clinical Hold On Phase 2 Clinical Trial of KVD824   Benzinga
06:30AM EDT  KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824   Business Wire
Mar 11, 2021
06:31AM EST  KalVista Pharmaceuticals Q3 EPS $(0.56) Down From $(0.52) YoY   Benzinga
Feb 18, 2021
08:40AM EST  Roth Capital Maintains Buy on KalVista Pharmaceuticals, Raises Price Target to $55   Benzinga
Feb 10, 2021
08:01AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
06:15AM EST  HC Wainwright & Co. Maintains Buy on KalVista Pharmaceuticals, Raises Price Target to $48   Benzinga
05:54AM EST  SVB Leerink Maintains Outperform on KalVista Pharmaceuticals, Raises Price Target to $51   Benzinga
02:54AM EST  Today's Daily Dose brings you news about KalVista's hereditary angioedema trial results, Heat Biologics' encouraging data from its phase II trial of HS-110 in non-small cell lung cancer, Gamida's presentation of full efficacy and safety results of Omidubicel in patients with hematologic malignancies and Neovasc regaining Nasdaq compliance.   RTTNews
Feb 9, 2021
04:01PM EST  KalVista Pharma Reports 4.5M Share Offering   Benzinga
03:31PM EST  KalVista Pharmaceuticals Shares Quiet; Hearing Jeffries Raises Price Target From $34 To Street-High $61; Traders Circulate Positive Comments From Note   Benzinga
02:47PM EST  Mid-Afternoon Market Update: Dow Rises 50 Points; Heat Biologics Shares Spike Higher   Benzinga
12:27PM EST  Mid-Day Market Update: KalVista Pharmaceuticals Jumps Following Positive HAE Readout; Ekso Bionics Shares Slide   Benzinga
10:25AM EST  Investors Cheer Positive Data From KalVista's KVD900 Mid-Stage Hereditary Angioedema Trial   Benzinga
10:23AM EST  Mid-Morning Market Update: Markets Mixed; Bitcoin Hits Record High   Benzinga
09:55AM EST  Shares of KalVista Pharmaceuticals, Inc. (KALV) surged over 135% on Tuesday morning after the drug maker reported positive results from a mid-stage trial of treatment for hereditary angioedema attacks.   RTTNews
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
06:38AM EST  KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks   Benzinga
Jan 26, 2021
06:21AM EST  Needham Maintains Buy on KalVista Pharmaceuticals, Raises Price Target to $32   Benzinga
Dec 14, 2020
04:05PM EST  Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting   GlobeNewswire Inc
Dec 10, 2020
07:13AM EST  KalVista Pharmaceuticals Q2 EPS $(0.58) Down From $(0.33) YoY   Benzinga
Nov 17, 2020
08:09AM EST  10 Biggest Price Target Changes For Tuesday   Benzinga
04:08AM EST  SVB Leerink Maintains Outperform on KalVista Pharmaceuticals, Raises Price Target to $39   Benzinga
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 4, 2020
05:11AM EST  Albert Cha Purchased 115,686 Shares of KalVista Pharmaceuticals @ Avg Price: $17.24/Share as per Form 4 Filing on November 3   Benzinga
Oct 22, 2020
07:52AM EDT  The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat   Benzinga
Oct 15, 2020
07:03AM EDT  KalVista pharmaceuticals Provided An Update On Its Oral Hereditary Angioedema Franchise; Co. Says KVD900 Completed Its Phase 2 Trial Recruitment And Expects To Have Data Before The End Of 2020   Benzinga
Sep 14, 2020
07:04AM EDT  KalVista Pharmaceuticals Q1 EPS $(0.61) Down From $(0.42) YoY   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC